Evonik Examining Construction of a Methyl Mercaptan Plant in the USA
Dr. Klaus Engel, member of the Executive Board of Evonik Industries responsible for the Chemicals Business Area, comments: "Our methionine activities are a significant part of our specialty chemicals portfolio. By expanding backward integration, we seek to strengthen this business consistently further." The concept of backward integration includes supplying Evonik's DL-methionine plants with all key intermediates such as acrolein and methyl mercaptan from in-house production. Evonik has been successfully doing this at its DL-methionine facilities in Antwerp (Belgium) and Wesseling (Germany).
Evonik anticipates that building the plant in Theodore could bring substantial savings in production and freight costs. The ability to integrate the methyl mercaptan plant directly into the present acrolein production could leverage further synergies. "We see the plans for a methyl mercaptan facility as preparation for expanding DL-methionine capacity further in Theodore," says Engel.
Topics
Organizations
Other news from the department manufacturing
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.